SGLT-话题@MedSci

#SGLT#

125篇内容 | 2795人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1793856, encodeId=82cd1e938562f, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=新版医保目录自3月1日起执行，原研SGLT2抑制剂（艾托格列净）价格再创新低！, objectType=article, longId=208138, objectId=ca0a2081382a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca0a2081382a, replyNumber=0, likeNumber=60, createdTime=2021-06-06, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca0a2081382a, moduleTitle=新版医保目录自3月1日起执行，原研SGLT2抑制剂（艾托格列净）价格再创新低！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca0a2081382a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793847, encodeId=f8941e9384709, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=SGLT2抑制剂Farxiga喜获FDA快速通道称号，以降低心力衰竭或心血管死亡住院风险, objectType=article, longId=197735, objectId=bb3a19e7357e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb3a19e7357e, replyNumber=0, likeNumber=55, createdTime=2020-11-25, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb3a19e7357e, moduleTitle=SGLT2抑制剂Farxiga喜获FDA快速通道称号，以降低心力衰竭或心血管死亡住院风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb3a19e7357e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793850, encodeId=50d11e9385084, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Diabetes Obes Metab：SGLT-2i与房颤的关系, objectType=article, longId=201708, objectId=479b201e089e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=479b201e089e, replyNumber=0, likeNumber=83, createdTime=2021-08-24, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=479b201e089e, moduleTitle=Diabetes Obes Metab：SGLT-2i与房颤的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=479b201e089e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793841, encodeId=51991e938412d, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Blood：SGLT2抑制剂依帕列净成功纠正了糖原贮积症Ib的中性粒细胞减少及其功能障碍, objectType=article, longId=192947, objectId=49b619294e48, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49b619294e48, replyNumber=0, likeNumber=64, createdTime=2020-07-09, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49b619294e48, moduleTitle=Blood：SGLT2抑制剂依帕列净成功纠正了糖原贮积症Ib的中性粒细胞减少及其功能障碍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49b619294e48)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793845, encodeId=c26d1e938456e, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=FDA：批准SGLT2抑制剂达格列净治疗射血分数降低心衰, objectType=article, longId=194242, objectId=464e1942427f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=464e1942427f, replyNumber=0, likeNumber=55, createdTime=2020-08-23, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=464e1942427f, moduleTitle=FDA：批准SGLT2抑制剂达格列净治疗射血分数降低心衰, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=464e1942427f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793851, encodeId=7fee1e9385160, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=JAMA：既能降糖又能保护心血管和肾脏？SGLT2抑制剂真的这么神奇吗？, objectType=article, longId=202549, objectId=a65c202549a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a65c202549a6, replyNumber=0, likeNumber=32, createdTime=2021-09-30, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a65c202549a6, moduleTitle=JAMA：既能降糖又能保护心血管和肾脏？SGLT2抑制剂真的这么神奇吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a65c202549a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793846, encodeId=ca871e93846d4, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=ADA 2020：SGLT2抑制剂Farxiga降低了心力衰竭患者患糖尿病的风险, objectType=article, longId=195939, objectId=e40a195939e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e40a195939e1, replyNumber=0, likeNumber=98, createdTime=2020-11-27, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e40a195939e1, moduleTitle=ADA 2020：SGLT2抑制剂Farxiga降低了心力衰竭患者患糖尿病的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e40a195939e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793843, encodeId=b88f1e93843d1, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=FDA批准阿斯利康的SGLT2抑制剂Farxiga，用于治疗射血分数降低的心力衰竭患者, objectType=article, longId=193624, objectId=acac19362471, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acac19362471, replyNumber=0, likeNumber=69, createdTime=2021-01-05, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acac19362471, moduleTitle=FDA批准阿斯利康的SGLT2抑制剂Farxiga，用于治疗射血分数降低的心力衰竭患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=acac19362471)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793836, encodeId=016c1e938360b, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=降糖药钠- 葡萄糖共转运蛋白2SGLT2 抑制剂成心衰治疗基石之一, objectType=article, longId=184434, objectId=14d118443425, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14d118443425, replyNumber=0, likeNumber=75, createdTime=2020-05-01, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14d118443425, moduleTitle=降糖药钠- 葡萄糖共转运蛋白2SGLT2 抑制剂成心衰治疗基石之一, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14d118443425)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793835, encodeId=f1291e9383555, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=SGLT2抑制剂临床应用专家指导建议解读 | CDS2019, objectType=article, longId=183456, objectId=a0c5183456e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0c5183456e9, replyNumber=0, likeNumber=66, createdTime=2020-09-01, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0c5183456e9, moduleTitle=SGLT2抑制剂临床应用专家指导建议解读 | CDS2019, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0c5183456e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793834, encodeId=9d031e93834f0, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=全球SGLT2i非糖尿病人群数据震撼发布丨葛均波院士、江晨恩教授两大牵头研究者解读DAPA-HF新证据, objectType=article, longId=183273, objectId=f3641832e38a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3641832e38a, replyNumber=0, likeNumber=102, createdTime=2020-07-09, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3641832e38a, moduleTitle=全球SGLT2i非糖尿病人群数据震撼发布丨葛均波院士、江晨恩教授两大牵头研究者解读DAPA-HF新证据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3641832e38a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793844, encodeId=ab2d1e93844a2, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Diabetes Obes Metab：SGLT2抑制剂与2型糖尿病患者糖尿病酮症酸中毒风险, objectType=article, longId=193883, objectId=9ea41938837b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ea41938837b, replyNumber=0, likeNumber=65, createdTime=2020-12-27, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ea41938837b, moduleTitle=Diabetes Obes Metab：SGLT2抑制剂与2型糖尿病患者糖尿病酮症酸中毒风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ea41938837b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793838, encodeId=a03e1e93838e7, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=阿斯利康的心力衰竭药物SGLT2抑制剂Farxiga获得FDA优先审查, objectType=article, longId=185842, objectId=eae01858423e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eae01858423e, replyNumber=0, likeNumber=68, createdTime=2020-04-13, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eae01858423e, moduleTitle=阿斯利康的心力衰竭药物SGLT2抑制剂Farxiga获得FDA优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eae01858423e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793839, encodeId=93da1e93839f5, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Lancet子刊：真实世界研究显示SGLT2抑制剂对糖尿病患者肾功能有获益, objectType=article, longId=186096, objectId=904518609696, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=904518609696, replyNumber=0, likeNumber=63, createdTime=2020-02-01, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=904518609696, moduleTitle=Lancet子刊：真实世界研究显示SGLT2抑制剂对糖尿病患者肾功能有获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=904518609696)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793837, encodeId=f5561e938375f, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=2019 日本建议：正确使用SGLT-2抑制剂, objectType=article, longId=184705, objectId=d6e2184e05d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6e2184e05d3, replyNumber=0, likeNumber=30, createdTime=2020-07-03, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6e2184e05d3, moduleTitle=2019 日本建议：正确使用SGLT-2抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6e2184e05d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793840, encodeId=37971e9384066, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=“灵魂砍价”药物还能防痛风？SGLT2抑制剂成“万金油”, objectType=article, longId=186358, objectId=6e021863583f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e021863583f, replyNumber=0, likeNumber=70, createdTime=2020-08-20, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e021863583f, moduleTitle=“灵魂砍价”药物还能防痛风？SGLT2抑制剂成“万金油”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e021863583f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793824, encodeId=cf651e9382450, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=2019 ADA：阿斯利康的SGLT2抑制剂达格列嗪可减轻2型糖尿病肾病, objectType=article, longId=168050, objectId=2d6716805018, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d6716805018, replyNumber=0, likeNumber=111, createdTime=2019-10-27, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d6716805018, moduleTitle=2019 ADA：阿斯利康的SGLT2抑制剂达格列嗪可减轻2型糖尿病肾病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d6716805018)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793833, encodeId=4cc41e9383314, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=2019 AHA：阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善, objectType=article, longId=183195, objectId=6133183195fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6133183195fa, replyNumber=0, likeNumber=64, createdTime=2020-06-30, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6133183195fa, moduleTitle=2019 AHA：阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6133183195fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793842, encodeId=be651e9384222, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=BMJ:使用SGLT2抑制剂可降低糖尿病患者严重肾功能事件风险, objectType=article, longId=193278, objectId=e2d81932e81e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2d81932e81e, replyNumber=0, likeNumber=68, createdTime=2020-10-25, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2d81932e81e, moduleTitle=BMJ:使用SGLT2抑制剂可降低糖尿病患者严重肾功能事件风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2d81932e81e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793832, encodeId=30061e938324a, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=阿斯利康的SGLT2抑制剂Farxiga获得FDA批准以减少因心力衰竭而住院的风险, objectType=article, longId=181704, objectId=6557181e048a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6557181e048a, replyNumber=0, likeNumber=59, createdTime=2020-07-02, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6557181e048a, moduleTitle=阿斯利康的SGLT2抑制剂Farxiga获得FDA批准以减少因心力衰竭而住院的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6557181e048a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

SGLT

2020-05-29

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

新版医保目录自3月1日起执行，原研SGLT2抑制剂（艾托格列净）价格再创新低！

2021-06-06

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

SGLT2抑制剂Farxiga喜获FDA快速通道称号，以降低心力衰竭或心血管死亡住院风险

2020-11-25

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Diabetes Obes Metab：SGLT-2i与房颤的关系

2021-08-24

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Blood：SGLT2抑制剂依帕列净成功纠正了糖原贮积症Ib的中性粒细胞减少及其功能障碍

2020-07-09

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

FDA：批准SGLT2抑制剂达格列净治疗射血分数降低心衰

2020-08-23

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

JAMA：既能降糖又能保护心血管和肾脏？SGLT2抑制剂真的这么神奇吗？

2021-09-30

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

ADA 2020：SGLT2抑制剂Farxiga降低了心力衰竭患者患糖尿病的风险

2020-11-27

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

FDA批准阿斯利康的SGLT2抑制剂Farxiga，用于治疗射血分数降低的心力衰竭患者

2021-01-05

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

降糖药钠- 葡萄糖共转运蛋白2SGLT2 抑制剂成心衰治疗基石之一

2020-05-01

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

SGLT2抑制剂临床应用专家指导建议解读 | CDS2019

2020-09-01

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

全球SGLT2i非糖尿病人群数据震撼发布丨葛均波院士、江晨恩教授两大牵头研究者解读DAPA-HF新证据

2020-07-09

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Diabetes Obes Metab：SGLT2抑制剂与2型糖尿病患者糖尿病酮症酸中毒风险

2020-12-27

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

阿斯利康的心力衰竭药物SGLT2抑制剂Farxiga获得FDA优先审查

2020-04-13

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Lancet子刊：真实世界研究显示SGLT2抑制剂对糖尿病患者肾功能有获益

2020-02-01

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

2019 日本建议：正确使用SGLT-2抑制剂

2020-07-03

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

“灵魂砍价”药物还能防痛风？SGLT2抑制剂成“万金油”

2020-08-20

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

2019 ADA：阿斯利康的SGLT2抑制剂达格列嗪可减轻2型糖尿病肾病

2019-10-27

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

2019 AHA：阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善

2020-06-30

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

BMJ:使用SGLT2抑制剂可降低糖尿病患者严重肾功能事件风险

2020-10-25

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

阿斯利康的SGLT2抑制剂Farxiga获得FDA批准以减少因心力衰竭而住院的风险

2020-07-02

科室
- - 订阅+
  - 更多科室
工具
服务